Andrew Gengos, Chief Financial Officer at Terns Pharmaceuticals, Inc. (TERN), bought 15,000 shares at $3.95 ($57K) on 2025-06-16, disclosed to the SEC on 2025-06-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.72 | 5,000 | $19K | 32.6% |
| 2 | $3.75 | 5,000 | $19K | 32.8% |
| 3 | $3.95 | 5,000 | $20K | 34.6% |
| Total | $3.81 avg | 15,000 | $57K | 100% |
| Filing → |
| ATHA | SELL | 2024-02-16 | $4K | — | Filing → |
| ATHA | SELL | 2024-01-08 | $4K | — | Filing → |
| ATHA | BUY | 2023-06-09 | $51K | — | Filing → |